AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04255017
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
Trial: NCT04255017
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
Trial: NCT01322451
Drug: GLPG0259 fumarate
RxNorm normalized name: fumarate
DrugBank: Calcium monoethylfumarate (DB15816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
Trial: NCT01322451
Drug: GLPG0259 free base
RxNorm normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single oral dose, GLPG0259, 50 mg solid formulation
Trial: NCT01823224
Drug: 2 capsules Oral Tylenol 2000 mg and IV salt water
RxNorm normalized name: acetaminophen
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly.
Trial: NCT00038636
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00038636
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04512066
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive oral risperidone QD.
Trial: NCT02957396
Drug: Finerenone (BAY94-8862): 20 mg intact tablet
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
Trial: NCT02957396
Drug: Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
Trial: NCT01234896
Drug: Nicotine Medicated Gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
Trial: NCT01234896
Drug: 4 mg Nicotine Gum
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
Trial: NCT01234896
Drug: 2 mg Nicotine Gum
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
Trial: NCT01234896
Drug: 4 mg Nicotine Lozenge
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
Trial: NCT04115111
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab in monotherapy as second line treatment
Trial: NCT01763710
Drug: Paclitaxel 80 mg/m2
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 days 1, 8 and 15
Trial: NCT01763710
Drug: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
Trial: NCT01763710
Drug: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
Trial: NCT01763710
Drug: Nab-paclitaxel 150 mg/m2 days 1 and 15
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 150 mg/m2 days 1 and 15
Trial: NCT02792465
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03758170
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Trial: NCT02390531
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Varying dosages in 10µl
Trial: NCT01911377
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT01911377
Drug: Normal Saline for Injection
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02957396
Drug: Finerenone (BAY94-8862): 20 mg suspension
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
Trial: NCT01723722
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
Trial: NCT01723722
Drug: Diluted Deodorized Tincture of Opium
DrugBank: Opium (DB11130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentration is 1:24 dilution for a concentration of 0.4%
Trial: NCT02771743
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02771743
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02771743
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02771743
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00325000
Drug: sertraline or amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02771743
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01877785
Drug: MHAA4549A
RxNorm normalized name: MHAA4549A
DrugBank: Gedivumab (DB15277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-ascending dose of MHAA4549A
Trial: NCT00806078
Drug: quinine sulfate
RxNorm normalized name: Quinine Sulfate
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 324 mg capsules (648 mg)
Trial: NCT02267278
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
Trial: NCT02267278
Drug: Pracinostat
RxNorm normalized name: Pracinostat
DrugBank: Pracinostat (DB05223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
Trial: NCT00103571
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00103571
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03007719
Drug: Fluorine F 18 Ara-G
RxNorm normalized name: Fluorine F-18
DrugBank: Fluorine F-18 (DB13134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01705587
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 microgram once-daily subcutaneous injection
Trial: NCT00461422
Drug: Ganirelix
RxNorm normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sc injection of Ganirelix 0.25 mg per day
Trial: NCT00535691
Drug: Tacrolimus Ointment 0.03%
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily, 14 days treatment.
Trial: NCT00535691
Drug: Tacrolimus Ointment 0.03%
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily, 14 days treatment.
Trial: NCT01234519
Drug: AEZS-108 at MTD
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
Trial: NCT00886106
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
Trial: NCT01532570
Drug: TA-650
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
Trial: NCT00289549
Drug: forodesine hydrochloride (BCX-1777)
RxNorm normalized name: terbinafine
DrugBank: Forodesine (DB06185)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: experimental, forodesine oral dose 200 mg administered daily.
Trial: NCT03858270
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
Trial: NCT01473303
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01473303
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00407550
Drug: gemcitabine HCL
RxNorm normalized name: gemcitabine HCl
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.
Trial: NCT00407550
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
Trial: NCT00407550
Drug: gemcitabine HCL
RxNorm normalized name: gemcitabine HCl
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
Trial: NCT02141217
Drug: Amoxicillin/clavulanate
RxNorm normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
Trial: NCT04202978
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab ：200mg intravenous injection d1 q3w
Trial: NCT04202978
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib：250mg/d P.O ,qd ,3weeks
Trial: NCT04202978
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin:130mg/m2 intravenous injection d1 q3w
Trial: NCT00364819
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
Trial: NCT02361619
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: probe
Trial: NCT02361619
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: probe
Trial: NCT02361619
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: probe
Trial: NCT02361619
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probe
Trial: NCT01545024
Drug: Sitagliptin, 50 mg once per day per os
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
Trial: NCT02403713
Drug: Fluticasone/formoterol BAI
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
Trial: NCT02403713
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol
Trial: NCT02403713
Drug: Fluticasone/formoterol PMDI without spacer
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone/Formoteral 125/5µg pMDI without spacer
Trial: NCT02403713
Drug: Fluticasone/formoterol PMDI with spacer
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone/Formoteral 125/5µg pMDI with spacer
Trial: NCT02403713
Drug: Fluticasone/formoterol PMDI without spacer low dose
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
Trial: NCT01978600
Drug: Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Trial: NCT01978600
Drug: Timolol Maleate 0.5%
RxNorm normalized name: TIMOLOL MALEATE 0.5% GEL,OPH
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Trial: NCT03588936
Drug: Nivolumab (.25 mg/kg)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Trial: NCT03588936
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 2 doses of tocilizumab
Trial: NCT01022151
Drug: 0.2 mL/kg of aminophylline 20 mg/mL [group A4]
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Trial: NCT01022151
Drug: 0.2 mL/kg of aminophylline 25 mg/mL [group A5]
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Trial: NCT00481572
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
Trial: NCT00481572
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
Trial: NCT01022151
Drug: Doxapram 1 mg/kg [group D]
DrugBank: Doxapram (DB00561)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Trial: NCT00143806
Drug: Transitioning patients from cyclosporine to alefacept
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03588936
Drug: Nivolumab (.5 mg/kg)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Trial: NCT03735264
Drug: Anlotinib Hydrochloride plus Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Trial: NCT01833455
Drug: PVC Suppression using Flecainide
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide will be administered to result in a reduction in PVC burden.
Trial: NCT00333164
Drug: Asprin, Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01529125
Drug: zidovudine, lamivudine, nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02966756
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; Oral
Trial: NCT00618254
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03883828
Drug: Chlorhexidine gluconate solution
RxNorm normalized name: chlorhexidine gluconate Irrigation Solution
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Trial: NCT03883828
Drug: Mupirocin Ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Trial: NCT01673399
Drug: Atosiban
RxNorm normalized name: atosiban
DrugBank: Atosiban (DB09059)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
Trial: NCT00759798
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
Trial: NCT00759798
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)
Trial: NCT01006057
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
Trial: NCT01006057
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
Trial: NCT01006057
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
Trial: NCT01006057
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
Trial: NCT01006057
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
Trial: NCT03258398
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
Trial: NCT02162121
Drug: Mepivacaine 1%
RxNorm normalized name: mepivacaine 1% injectable solution
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02162121
Drug: Levobupivacaine 0,5%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02162121
Drug: Ropivacaine 0,2%
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no